Effect of incomplete revascularisation by percutaneous coronary intervention on the outcome and prognosis in aged patients with multivessel coronary artery disease trimetazidine. (12th October 2011)

• Record Type: Journal Article
• Authors: Hailong, Ge
• Is Part Of: Heart. Volume 97(2011)Supplement 3
• Page Start: A165
• Page End: A166
• Publication Date: 2011-10-12
• Subjects: Heart -- Diseases -- Treatment -- Periodicals; Cardiology -- Periodicals; 616.12
• DOI: 10.1136/heartjnl-2011-300867.487
• Languages: English
• ISSNs: 1355-6037

Abstract

Abstract : Objective: To evaluate the influence of trimetazidine on efficiency and exercise tolerance in aged patients with multivessel coronary artery disease undergoing incomplete revascularisation by percutaneous coronary intervention (PCI). Methods: Seventy three aged patients with multivessel coronary artery disease complicated undergoing incomplete revascularisation by PCI were divided into trimetazidine group (n=38) and routine therapy group (n=35). MACE events, angina frequency, angina duration and number of CCS class were follow-up at 12 months after PCI. Results: The incidence of MACE after 12 months follow-up showed there were significantly differences between two groups, p<0.05. Angina and CCS class were all significantly reduced in trimetazidine group compared to routine therapy group (p<0.05). LVEF and mean distance of 6-min walk test were significantly increased in trimetazidine group after 12 months than those at baseline (p<0.5). The distance of 6-min walk-test in trimetazidine group was longer than that in routine therapy group (p<0.05). Conclusion: Trimetazidine could reduce the frequency of angina pectoris events and myocardial damage during PCL. It also improves left ventricular function during follow-up after PCI.